Mirum to purchase Bluejay for as much as $820m in uncommon liver illness push
Mirum Prescription drugs has agreed to amass Bluejay Therapeutics in a deal value as much as $820m, including a Part III liver illness candidate to its portfolio.
In keeping with the settlement, US-based Mirum pays $250m in money and $370m in its personal inventory upfront to purchase the personal biotech. Bluejay can also be in line to obtain an additional $200m in potential sales-based milestones.
Uncover B2B Advertising That Performs
Mix enterprise intelligence and editorial excellence to succeed in engaged professionals throughout 36 main media platforms.
The deal provides Mirum entry to brelovitug, Bluejay’s monoclonal antibody (mAb) at present being evaluated in a Part III trial for continual hepatitis D, a uncommon and extreme liver an infection for which there aren’t any US Meals and Drug Administration (FDA)-approved therapies. Gilead’s Hepcludex (bulevirtide) is authorised as a hepatitis D therapy within the EU.
Solely occuring in folks already contaminated with hepatitis B because of the floor proteins wanted for viral replication, continual hepatitis D is taken into account probably the most extreme sort of continual viral hepatitis and results in cirrhosis, liver failure, and liver most cancers.
Brelovitug neutralises hepatitis D and hepatitis B virusus by binding to floor antigens, clearing hepatitis B Floor Antigen (HBsAg)-containing particles and activating antigen-specific T cells.
In November 2025, Bluejay reported constructive information from a Part II examine evaluating brelovitug in sufferers with continual hepatitis D. The drug achieved a 100% virologic response, together with helpful results on liver irritation and viral load discount.
The continued world AZURE Part III programme is at present enrolling sufferers, with top-line information anticipated in H2 2026. Mirum anticipates submitting an software to the FDA in 2027, with a launch occurring in the identical yr.
Mirum mentioned it has additionally secured $200m by a personal placement with new and current healthcare traders to assist fund the drug’s improvement and commercialisation.
Mirum’s business portfolio consists of Livmarli (maralixibat) for continual itching resulting from Alagille syndrome, Cholbam (cholic acid) for bile acid synthesis issues, and Ctexli (chenodiol) for lipid storage illness cerebrotendinous xanthomatosis.
The latter two merchandise had been acquired by Mirum in a buyout of Travere’s bile acid product portfolio for as much as $445m in 2023.
Mirum’s CEO Chris Peetz mentioned: “This acquisition matches squarely with what we do greatest – advancing high-impact medicines for sufferers with uncommon ailments by disciplined improvement, regulatory innovation, and business excellence.”
Mirum’s pipeline consists of ileal bile acid transporter inhibitor volixibat, which is in two Part IIb research (NCT05050136, NCT04663308) for 2 varieties of cholangitis. The corporate additionally has MRM-3379, a PDE4D inhibitor in a Part II trial (NCT07209462) for the therapy of fragile X syndrome.
Peetz added: “Brelovitug in hepatitis D leverages our deep experience in uncommon liver illness and builds on the relationships we’ve established with key suppliers by the volixibat and Livmarli programmes.”
Join our each day information round-up!
Give your small business an edge with our main trade insights.
